• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Protonix (pantoprazole sodium) For Delayed-Release Oral Suspension and Delayed-Release Tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  

 

December 2013

Summary View

ADVERSE REACTIONS

Post marketing Experience
  • agranulocytosis, pancytopenia and taste disorders (ageusia, dyseusia)

 

 

May 2012

Summary View

 

5 WARNINGS AND PRECAUTIONS

5.8 Concomitant use of PROTONIX with Methotrexate
  • Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose .....

7 DRUG INTERACTIONS

7.6 Methotrexate
  • Case reports, published population suggest that concomitant administration of PPIs and methotrexate .....